Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Twinrix versus monovalent hepatitis A and B vaccine challenge study at 48 months in adults older than 41 years
2008-000526-39Phase 4Completed
- Sponsor
- GSK
- Start
- Apr 2008
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of hepatitis b vaccine recombinant, Hepatitis B vaccine, Hepatitis A virus vaccine and Recombivax HB in hepatitis A (HAV) and hepatitis B (HBV) (3 arms), sponsored by GSK. Primary endpoints: Anti-HAV immune response to challenge dose and Anti-HBs immune response to challenge dose. Started Apr 2008; status: completed.
02
Drugs
hepatitis b vaccine recombinantHepatitis B vaccineHepatitis A virus vaccineRecombivax HB
03
Conditions
hepatitis A (HAV)hepatitis B (HBV)
Beyond the preview
Go deeper on 2008-000526-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000526-39.